Literature DB >> 10789357

Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

J Munro1, D O'Sullivan, C Andrews, A Arana, A Mortimer, R Kerwin.   

Abstract

BACKGROUND: People prescribed clozapine for treatment-resistant schizophrenia have mandatory haematological monitoring through a case register for identifying reversible neutropenia. AIMS: To quantify risk factors for agranulocytosis in subjects receiving clozapine.
METHOD: Data from 12,760 subjects registered to receive clozapine from January 1990 to April 1997 were analysed. Risk factors for agranulocytosis were quantified using a Cox proportional-hazards regression analysis.
RESULTS: The risk for agranulocytosis in Asian subjects was 2.4 times that in Caucasians (P = 0.03). There was an age-related increase in risk of 53% per decade (P = 0.0001).
CONCLUSIONS: The case register yielded valuable information for guiding research into the causes of the haematological reactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10789357     DOI: 10.1192/bjp.175.6.576

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  51 in total

Review 1.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options.

Authors:  Herbert Y Meltzer
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

3.  Managing pathologic aggression in people with psychotic disorders.

Authors:  Dominique Bourget; Alain Labelle
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

4.  Clozapine underutilization and discontinuation in African Americans due to leucopenia.

Authors:  Deanna L Kelly; Julie Kreyenbuhl; Lisa Dixon; Raymond C Love; Deborah Medoff; Robert R Conley
Journal:  Schizophr Bull       Date:  2006-12-14       Impact factor: 9.306

5.  Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Authors:  Mina Boazak; Benjamin Kahn; Lindsay Cox; James Ragazino; David R Goldsmith; Robert O Cotes
Journal:  Clin Schizophr Relat Psychoses       Date:  2018-06-26

6.  Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

Authors:  Charles M Richardson; Erica A Davis; Gopal R Vyas; Bethany A DiPaula; Robert P McMahon; Deanna L Kelly
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

7.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

8.  Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Authors:  Pudtan Phanthunane; Theo Vos; Harvey Whiteford; Melanie Bertram
Journal:  Cost Eff Resour Alloc       Date:  2011-05-13

Review 9.  Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma.

Authors:  Nazife Gamze Usta; Cana Aksoy Poyraz; Melih Aktan; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

Review 10.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.